Test Price
2,800 AED✅ Home Collection Available
POLR3A Gene Leukodystrophy Hypomyelinating Type 7 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين POLR3A لاعتلال بيضاء الدماغ ناقص الميالين النوع 7 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary: This advanced genetic test delivers 99.9% diagnostic sensitivity using ISO-accredited Genetic Test clinical guidance by DHA-licensed physicians.
ملخص تنفيذي: يوفر هذا الاختبار دقة تشخيصية تصل إلى 99.9% عبر تقنية التسلسل الجيني المعتمدة من الآيزو، مع خدمة سحب منزلي متميزة على مدار الساعة (8 صباحًا - 11 مساءً)، وشحن مبرد، وإرشاد سريري بعد النتيجة من أطباء هيئة الصحة بدبي. للتحقق من التأمين، تواصل واتساب: +971 54 548 8731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-registered specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
The POLR3A gene test identifies pathogenic variants associated with hypomyelinating leukodystrophy type 7, a severe neurological disorder characterized by delayed myelination, motor regression, and cognitive decline. This NGS-based assay screens the entire coding region with >100x read depth, enabling early diagnosis and informed family planning. يحدد هذا الاختبار الطفرات الممرضة في جين POLR3A المسؤولة عن اعتلال بيضاء الدماغ ناقص الميالين النوع 7، مما يساعد في التشخيص المبكر والاستشارة الوراثية.
Sample Types: Whole Blood (EDTA), Extracted DNA, Dried Blood Spot on FTA Card. Turnaround Time: 3–4 Weeks.
| Feature | Our Test (POLR3A NGS) | Closest Alternative |
|---|---|---|
| Methodology | Full Gene Next Generation Sequencing + Sanger Confirmation | Single-site PCR / Sanger only (limited coverage) |
| Diagnostic Yield | Covers all exons, splice sites, and regulatory regions – >99% sensitivity | Partial gene screening; misses deep intronic or novel variants |
| Turnaround Time | 3–4 weeks with rapid pre-authorization | 6–8 weeks (fragmented workflows) |
| Regulatory Compliance | Full UAE DHA, CDS Law 2026, ISO 9001:2015, PDPL | May lack local genetic counselling mandate |
Physician Insight & Safety Protocol
Note from Dr. PRABHAKAR REDDY (DHA: 61713011), Consulting Neurologist: "The POLR3A test is a cornerstone for confirming hypomyelinating leukodystrophy type 7, especially in children presenting with spasticity, ataxia, and MRI evidence of hypomyelination. A positive result must be correlated with clinical and neuroimaging findings; genetic counselling is essential before testing. We recommend this test only after detailed neurological evaluation and pedigree analysis."
⚠️ Medication Warning
Do not discontinue any prescribed medication without consulting your physician. This genetic test does not replace ongoing neurological management.
Safety Exclusion Criteria & ER Red Flags
- Exclusion: Patients who have not undergone a genetic counselling session with a DHA-licensed counsellor (mandatory per UAE CDS Law 2026).
- Exclusion: Minors without legal guardian consent in line with UAE genetic testing regulations.
- ER Red Flag: If you or your child experiences sudden loss of consciousness, uncontrolled seizures, or respiratory distress, seek emergency care immediately before scheduling this test.
- ER Red Flag: Acute neurological deterioration (severe headache, vision changes, paralysis) requires emergency evaluation, not elective genetic testing.
Patient FAQ & Clinical Guidance
1. How accurate is the POLR3A Genetic Test for diagnosing leukodystrophy?
This achieves over 99.9% analytical sensitivity for single nucleotide variants and small indels within the POLR3A gene, providing a definitive molecular diagnosis when combined with clinical correlation and MRI findings.
2. What preparation is required before sample collection?
A mandatory genetic counselling session is needed to draw a detailed family pedigree, review neurological history, and obtain informed consent in compliance with UAE Federal Decree-Law No. 41 of 2024. No fasting or medication changes are required.
3. هل يمكن إجراء الاختبار للأطفال في الإمارات؟
نعم، يمكن إجراء الاختبار للأطفال شريطة موافقة الوصي القانوني وبعد جلسة استشارة وراثية كاملة وفقًا لقانون الاختبارات الجينية لدولة الإمارات (قانون رقم 41 لسنة 2024). لا يتطلب الاختبار صيامًا، ويتم سحب العينة في المنزل.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians